IRRAS

Focus: IRRAS is a Swedish medical device biotechnology company specializing in intracranial drainage, access, and monitoring solutions for neurosurgical conditions. The company focuses on a narrow but critical niche within CNS care with limited public scale data.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About IRRAS

AI assessmentNot Hiring

No open roles listed right now. Follow IRRAS to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

IRRAflow® CNS

Intracranial Hemorrhage

N/A

Clinical Trials (1)

NCT06649097Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System

N/A

Help build intelligence for IRRAS

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline on high-acuity CNS conditions (intracranial hemorrhage, intraventricular hemorrhage) with significant unmet clinical needs
Swedish biotech base in Stockholm provides access to strong European regulatory pathways and healthcare infrastructure
Specialized device-based approach differentiates from crowded pharma pipeline landscape

Watch Out For

No active hiring and zero open positions indicate company is not in growth/expansion phase
Limited public financial data, funding information, and employee count raise transparency and stability concerns
Early-stage pipeline with five programs in trials but no defined development phases suggests clinical validation risk

Generated by Claude from IRRAS's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

IRRAflow

Intraventricular Hemorrhage

N/A

Clinical Trials (1)

NCT05204849ACTIVE Study - Use of ACTIVE Fluid Exchange to Treat Intraventricular Hemorrhage

N/A

IRRAflow with Active Fluid Exchange System

Intraventricular Hemorrhage

N/A

Clinical Trials (1)

NCT05649904AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis

N/A

IRRAflow

Cerebral Hemorrhage

N/A

Clinical Trials (1)

NCT05118997Active Removal of IntraCerebral Hematoma Via Active Irrigation

N/A

IRRAflow® Active Fluid Exchange System

Intraventricular Hemorrhage (IVH)

N/A

Clinical Trials (1)

NCT05970549Intraventricular Catheter System for IVH

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo